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        Immunosurveillance for intracellular pathogens 
is primarily mediated by conventional TCR         
CD8 T lymphocytes that recognize pathogen-
derived oligopeptides presented by   “  classical  ”   
MHC class Ia molecules (the H-2K, D, and L 
molecules in the mouse). Yet, a sizeable number 
of H-2D distal genes in the Q, T, and M regions 
of the mouse MHC and the non  –  MHC-linked 
  CD1   and   MR1   genes encode       2   microglobulin 
(      2  m)  –  associated class I glycoproteins. Compared 
with MHC class Ia molecules, these   “  nonclassi-
cal  ”   class Ib molecules have limited polymor-
phism, low-level ubiquitous or tissue-specifi  c 
expression, truncated cytoplasmic/transmem-
brane domains, and/or alternative splicing pat-
terns (  1  ). Several class Ib molecules have been 
shown to mediate immunoregulatory as well as 
nonimmunological functions (  2  –  6  ). 
  CD8 T cells restricted by MHC class Ib 
molecules have also been implicated in micro-
bial defense. In particular, the mouse class Ib 
molecules H2-M3, CD1d (and human CD1), 
and Qa-1 (and its human orthologue HLA-E) 
serve as TCR restriction elements for CD8 T 
cells that provide immunity against intracellular 
bacteria, including   Listeria monocytogenes  ,   Myco-
bacterium tuberculosis  , and   Salmonella typhimurium  , 
respectively (  7  –  9  ). H2-M3 preferentially pre-
sents   N  -formyl peptides, and CD1 presents my-
cobacterial lipid antigens to nonconventional T 
cells implicated in immunity to   M. tuberculosis   
infection. Other than Qa-1 and HLA-E, which 
present the GroEL nonamer peptide from   S. typhi  , 
there are few examples of class Ib molecules that 
present   “  class Ia  –  like  ”   peptides and none that 
serve as ligands for CD8 T cells that fi  ght non-
bacterial pathogens (  1  ). 
  Limited evidence suggests that class Ib  – 
restricted CD8 T cells may also contribute to 
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    Although immunity against intracellular pathogens is primarily provided by CD8 T lympho-
cytes that recognize pathogen-derived peptides presented by major histocompatibility com-
plex (MHC) class Ia molecules, MHC class Ib  –  restricted CD8 T cells have been implicated in 
antiviral immunity. Using mouse polyoma virus (PyV), we found that MHC class Ia  –  defi  cient 
(K  b    /     D  b    /     ) mice effi  ciently control this persistently infecting mouse pathogen. CD8 T cell 
depletion mitigates clearance of PyV in K  b    /     D  b    /      mice. We identifi  ed the ligand for PyV-
specifi  c CD8 T cells in K  b    /     D  b    /      mice as a nonamer peptide from the VP2 capsid protein 
presented by Q9, a member of the       2   microglobulin  –  associated Qa-2 family. Using Q9-VP2 
tetramers, we monitored delayed but progressive expansion of these antigen-specifi  c CD8         
T cells in K  b    /     D  b    /      mice. Importantly, we demonstrate that Q9-VP2  –  specifi  c CD8 T cells 
more effectively clear wild-type PyV than a VP2 epitope  null   mutant PyV. Finally, we show 
that wild-type mice also generate Q9-restricted VP2 epitope  –  specifi  c CD8 T cells to PyV 
infection. To our knowledge, this is the fi  rst evidence for a defi  ned MHC class Ib  –  restricted 
antiviral CD8 T cell response that contributes to host defense. This study motivates efforts to 
uncover MHC class Ib  –  restricted CD8 T cell responses in other viral infections, and given the 
limited polymorphism of MHC class Ib molecules, it raises the possibility of developing pep-
tide-based viral vaccines having broad coverage across MHC haplotypes. 1648 MHC CLASS IB  –  RESTRICTED ANTIVIRAL CD8 T CELLS   | Swanson et al. 
induced tumors of B6 mice (3 out of 17 K  b    /     D  b    /      mice 
developed tumors at 7 mo postinfection [p.i.]). Consistent 
with their tumor resistance, K  b    /     D  b    /      mice clear acute 
PyV infection and check persistent viral replication with an 
effi   ciency similar to B6 mice (  Fig. 1 A  ).   Compared with B6 
mice, however, K  b    /     D  b    /      mice had a signifi  cantly higher 
viral load in the kidney (and a higher, but not signifi  cant, viral 
load in the spleen) at day 8 p.i. It is interesting to note that 
with this apparent lag in control of acute PyV infection, CD8 
T cell numbers in K  b    /     D  b    /      mice do not appreciably 
change until 25 d p.i. but then progressively increase well into 
the persistent phase of infection (  Fig. 1 B  ). K  b    /     D  b    /      mice 
depleted of CD8 T cells manifested signifi  cantly higher viral 
loads than those mice given control rat IgG (  Fig. 1 C  ). Col-
lectively, these data implicate non  –  MHC class Ia  –  restricted 
CD8         T cells in anti-PyV immunity in K  b    /     D  b    /      mice. 
  Identifi  cation of the ligand for MHC class Ib  –  restricted 
PyV-specifi  c CD8 T cells 
  Because of the small CD8 T cell compartment in K  b    /     D  b    /      
mice (    2% of splenic CD8 T cells in B6 mice), we were un-
able to reliably and consistently detect PyV-specifi  c CD8 T 
cell responses in K  b    /     D  b    /      mice ex vivo by IFN-     intra-
cellular staining assays. To circumvent this obstacle, we iso-
lated and established continuous cultures of T cell clones 
from individual K  b    /     D  b    /      mice that specifi  cally recognized 
PyV-infected APCs (  Fig. 2 A  ).   These CD8         (unpublished 
data) T cell clones provided the cellular reagents to defi  ne the 
ligands for the anti-PyV CD8 T cells in K  b    /     D  b    /      mice. 
  PyV-infected spleen cells from mice lacking all       2  m-asso-
ciated class I molecules (K  b    /     D  b    /           2  m      /     ) failed to stimu-
late these K  b    /     D  b    /      mouse  –  derived CD8 T cell clones, 
narrowing the candidate restriction elements to a       2  m-asso-
ciated class I molecule (  Fig. 2 B  ). Infected splenic APCs from 
B6 mice with targeted disruption of   H2-M3  ,   CD1d   (  Fig. 2 B  ), 
or   Qa-1   (unpublished data) genes were recognized by the T 
cell clones, excluding these molecules as MHC class Ib  –  re-
stricting elements. In contrast, the T cell clones did not pro-
duce IFN-     when co-cultured with infected APCs from 
B6.K1 mice, a congenic B6 mouse strain null for the   Qa-2   
locus, implicating a Qa-2 gene product as the MHC class Ib  –
  restricting element. 
  Concomitant with these restriction mapping studies, 
we used libraries of 15-17mer overlapping peptides cover-
ing all six PyV proteins in an MHC-unbiased approach to 
defi  ne viral epitopes recognized by the K  b    /     D  b    /      PyV-
specifi  c T cell clones. By testing the antigenicity of individ-
ual peptides in IFN-     ELISPOT assays, we found that only 
one 15mer peptide corresponding to aa 136  –  150 within the 
VP2 minor capsid protein, designated peptide 28 (  Table I  ), 
stimulated each of two cloned lines isolated from diff  erent 
K  b    /     D  b    /      mice (unpublished data).   Coincidentally, this 
peptide contained sequences that satisfi  ed the MHC anchor 
consensus motif for 8-9mer peptides bound to Qa-2 mole-
cules: histidine at position 7 (numbered from the amino 
end), and a hydrophobic carboxy terminus. Of three 9mers 
viral immunity. Early studies identifi  ed a nonformylated pep-
tide derived from the infl  uenza virus hemagglutinin that in-
duced an in vitro primary expansion of H2-M3  –  restricted 
CD8 CTLs, but these CTLs were unable to kill infl  uenza 
virus  –  infected cells (  10, 11  ). In addition, HLA-E  –  restricted 
TCR         CD8 CTL cloned lines recognizing a nonamer pep-
tide derived from the UL40 protein of human CMV have 
been previously described (  12  ). Recently, Braaten et al. dem-
onstrated that       2  m-dependent TCR         CD8 T cells in mice 
selectively lacking MHC class Ia molecules (K  b    /     D  b    /      mice) 
controlled chronic infection by rodent     -herpesvirus 68, 
although the class Ib  –  restricting molecule and viral epitope 
remain to be identifi  ed (  13  ). 
  Polyomaviruses are highly prevalent vertebrate pathogens 
that generally cause a self-limited acute infection followed by 
long-term asymptomatic persistent infection in their natural 
host reservoir (  14  ). In the immunosuppressed population, 
human polyomaviruses JC and BK can reactivate with se-
verely debilitating consequences, including a typically fatal 
central nervous system demyelinating disease and allograft 
nephropathy, respectively (  15, 16  ). Recently, two new hu-
man polyomaviruses have been identifi  ed in respiratory tract 
infections, and another has been associated with the cutaneous 
malignancy Merkel cell carcinoma (  17  –  19  ). Mouse polyoma-
virus (PyV) establishes low-level systemic persistent infection 
and causes tumors in immunocompromised mice and neona-
tally infected mice of certain inbred strains (  20  ). The     5-kb 
double-stranded PyV genome encodes only six proteins, 
three nonstructural proteins (small T, middle T [MT], and 
large T [LT] antigens) and three capsid proteins (VP1, VP2, 
and VP3). Interestingly, only peptides derived from the T 
antigens have been defi  ned as epitopes for MHC class Ia  – 
restricted PyV-specifi  c CD8 T cells (  14, 21  ). 
  In this study, we investigated whether PyV infection elic-
its virus-specifi  c CD8 T cells restricted by MHC class Ib mol-
ecules. We previously showed that       2  m      /      mice ineffi   ciently 
control PyV infection, as indicated by the realization of this 
virus  ’  s oncogenic potential (  22  ). Unexpectedly, K  b    /     D  b    /      
mice are highly resistant to tumor formation and effi   ciently 
control PyV infection, implicating MHC class Ia  –  indepen-
dent CD8 T cells in surveillance for PyV-infected cells. 
We identifi  ed the ligand for the dominant PyV-specifi  c CD8 
T cell response in K  b    /     D  b    /      mice as a VP2-derived nona-
meric peptide presented by Q9, a member of the Qa-2 family 
of Q region  –  encoded MHC class Ib molecules. Importantly, 
PyV infection also elicits Q9-restricted VP2-specifi  c CD8 T 
cells in wild-type mice. Our fi  ndings provide the fi  rst formal 
demonstration of an antigen-specifi  c class Ib  –  restricted CD8 
T cell response that confers immunity to a viral infection. 
    RESULTS   
  MHC class Ia  –  defi  cient mice control PyV infection 
  In contrast to       2  m      /      mice, which are both MHC class Ia  –   
and class Ib  –  defi  cient and highly susceptible to PyV tumori-
genesis (  22  ), we observed that PyV-infected MHC class 
Ia  –  defi  cient K  b    /     D  b    /      mice retain the resistance to PyV-JEM VOL. 205, July 7, 2008 
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used TAP2-defi  cient, MHC class Ia  –  negative B78H1 lines sta-
bly transfected with TAP2 and Q8 (H1Q8TAP.11), TAP2 and 
Q9 (H1Q9TAP11), or TAP2 and empty vector (H1TAP.11) 
as target cells in cytotoxicity assays (  26  ). As shown in   Fig. 2 D  , 
only VP2.139 peptide  –  loaded cells expressing Q9 were rec-
ognized by these CD8 T cell clones. Collectively, these re-
sults defi  ne Q9-VP2.139 as the ligand for TCRs expressed 
by the PyV-specifi  c CD8 T cell clone lines isolated from 
K  b    /     D  b    /      mice. 
  Visualization of Q9-VP2.139  –  specifi  c CD8 T cells 
in K  b    /     D  b    /      mice 
  We constructed Q9 tetramers complexed to the VP2.139 pep-
tide to monitor the evolution of these novel antigen-specifi  c 
CD8 T cells through the course of PyV infection. To confi  rm 
the specifi  city of the Q9-VP2.139 tetramers, we determined 
that tetramer  +   CD8 T cells were readily detectable in spleens 
of K  b    /     D  b    /      mice infected by wild-type PyV, but not in 
uninfected mice (  Fig. 3 A  ).   Moreover, the Q9-VP2.139 tetra-
mer did not stain CD8 T cells in mice infected by a mutant 
having a histidine at P7 within the VP2 aa sequence 133  –
  151 (  Table II  ), only 139  –  147 of the VP2 PyV capsid pro-
tein (VP2.139) stimulated intracellular IFN-     production 
by all of the K  b    /     D  b    /      mouse  –  derived CD8 T cell clones 
(  Fig. 2 C  ).   Single residue truncations of the VP2.139 peptide 
at the carboxy or amino terminus resulted in peptides that 
did not stimulate any of the clones, indicating that aa 139  –
  147 of VP2 represent the minimum Qa-2  –  restricted epitope 
(unpublished data). Interestingly, the carboxy terminus of 
VP2.139 is occupied by tryptophan, a residue not detected 
at this position among endogenous peptides eluted from Qa-2 
molecules (  23  ); however, the Qa-2 F pocket is relatively spa-
cious and can accommodate large side chains (  24  ). 
  The Qa-2 family is composed of several members, of 
which Q9 is among the most thoroughly characterized mouse 
class Ib proteins. Q9 and another Qa-2 family member, Q8, 
share largely overlapping peptide-binding motifs, despite hav-
ing   >  20 aa diff  erences in the     1 and     2 domains (  25  ). To 
determine whether Q8 and/or Q9 present the VP2.139 epi-
tope to the K  b    /     D  b    /      PyV-specifi  c CD8 T cell clones, we 
    Figure 1.         K  b    /     D  b    /      mice control PyV replication.   (A) Levels of PyV DNA (  ±  SEM) in organs at the indicated days p.i. (B) Number of splenic and lung 
CD8 T cells (  ±  SD) in PyV-infected K  b   /   D b   /     mice over time. (C) K  b   /   D b   /     mice received either CD8-depleting mAb or an isotype control rat IgG, and 
the PyV genome copy numbers (  ±  SEM) in the indicated organs were assayed on day 35 p.i. Data are the mean of three to fi  ve mice per group and are 
representative of two independent experiments. *, P   ≤   0.05; **, P   ≤   0.01.     1650 MHC CLASS IB  –  RESTRICTED ANTIVIRAL CD8 T CELLS   | Swanson et al. 
  Chronic encounter by cognate antigen typically directs 
MHC class Ia  –  restricted CD8 T cells toward an eff  ector dif-
ferentiation state having curtailed eff  ector competency. To de-
termine whether persistent PyV infection similarly aff  ected this 
antiviral CD8 T cell response in K  b    /     D  b    /      mice, we pheno-
typically and functionally characterized VP2.139-specifi  c CD8 
T cells during their expansion (day 35 p.i.) and long-term 
maintenance (day 178 p.i.) phases. At day 35 p.i., Q9-VP2.139 
tetramer  +   CD8 T cells displayed an overall eff  ector-like pheno-
type (CD44  hi  , CD94/NKG2  hi  , and CD122  lo  ; unpublished 
data), but with a mixed CD43 (clone 1B11 epitope), CD62L-
selectin, and IL-7R     (CD127) expression pattern, and elevated 
expression of killer cell lectin-like receptor subfamily G, mem-
ber 1 (KLRG1), a marker of short-lived eff  ector CD8 T cells 
(  Fig. 3 C  ) (  28, 29  ). By day 178 p.i., however, the VP2.139-specifi  c 
PyV in which the Q9-anchoring histidine in the VP2.139 epi-
tope was replaced by alanine (designated A2.H145A). Direct 
ex vivo Q9-VP2.139 tetramer staining showed that PyV-
infected K  b    /     D  b    /      mice did not generate a detectable anti-
gen-specifi  c CD8 T cell response in either spleen or lung until 
day 8 of infection, at which point VP2.139 epitope  –  specifi  c 
CD8 T cells steadily increased in both frequency and magni-
tude into persistent infection (  Fig. 3 B  ). Notably, by 80 d p.i., 
VP2.139-specifi  c CD8 T cells represented nearly 80% of CD8 
T cells in the lung and blood (unpublished data), and 40% of 
splenic CD8 T cells. This T cell response profi  le diff  ers consid-
erably from that of MHC class Ia  –  restricted anti-PyV CD8 
T cell responses, where tetramer  +   CD8 T cells are typically de-
tected by 5 d p.i., peak in magnitude by 8 d p.i., and then quickly 
contract to a lower long-term steady-state level (  14, 27  ). 
    Figure 2.         Q9-VP2.139 is the ligand for PyV-specifi  c K  b    /     D  b    /      CD8 T cell clones.   CD8 T cell clones isolated from PyV-infected K  b   /   D b   /     mice 
were stimulated by PyV-infected or uninfected K  b   /   D b   /     splenocytes (A) or PyV-infected or uninfected splenocytes from mice of the indicated strains 
(B) for 5 h, and analyzed for intracellular IFN-    . Data in B show the frequency of IFN-      –  producing clone C3-8 cells; the same response pattern is shown 
by clone C1-21 (unpublished data). (C) Frequency of T cell clones stained intracellularly by anti  –  IFN-     after stimulation by K  b   /   D b   /     splenocytes in the 
presence of VP2.139 peptide or no added peptide. (D) Cytotoxic activity (  ±  SD) by C1-21 and C3-8 T cell clones against VP2.139  peptide – coated  control 
target cells (H1TAP.11) and target cells expressing Q8 (H1Q8TAP.11) or Q9 (H1Q9TAP.11). Without peptide, no specifi  c lysis was seen by either cloned line 
against any of these target cells (unpublished data).     
    Table I.        Overlapping VP2 peptides used to map the Qa-2  –  restricted PyV-specifi  c T cell epitope 
Peptide no.
Peptide 27 F P G V N Q F A H A L N V V H
Peptide 28 Q F A H A L N V V H D W G H G
Peptide 29 L N V V H D W G H G L L H S VJEM VOL. 205, July 7, 2008 
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class Ia  –  restricted antiviral CD8 T cells maintained in the set-
ting of persistent viral infections, including those responding 
to PyV infection (  33  ). 
  VP2.139-specifi  c CD8 T cells in K  b    /     D  b    /      mice ex-
hibited pronounced functional impairment. Throughout the 
course of PyV infection,   <  50% of VP2.139-specifi  c CD8 T 
cells detected by tetramers produced intracellular IFN-     af-
ter VP2.139 peptide stimulation (  Fig. 4 A  ).   Interestingly, a 
fraction of the VP2.139-specifi  c CD8 T cells acquired the 
ability to coproduce IFN-     and TNF-     at a late time point, 
when persistent infection viral loads had fallen (  Fig. 1 A   and 
  Fig. 4 B  ). To assay antigen-specifi  c cytotoxic activity in vivo, 
CD8 T cells assumed an unusual phenotype overlapping both 
eff  ector and memory phenotypic profi  les, consistent with 
repetitive antigenic stimulation of memory CD8 T cells 
(  30, 31  ). Although nearly all of the maintenance-phase 
Q9-VP2.139 tetramer  +   CD8 T cells were CD62L  lo  , they had 
reduced expression of CD27 and CD43, and increased lev-
els of surface IL-7R    . This CD27  lo  CD43  lo  CD127  hi   profi  le 
has been recently ascribed to CD8 T cells having strong recall 
response capability (  32  ). Notably, VP2.139-specifi  c CD8 
T cells at days 35 and 178 p.i. did not express the inhibi-
tory programmed death 1 receptor (unpublished data), which 
is often present on the surface of functionally impaired MHC 
    Table II.       Peptides  fi  tting the Q9 peptide-binding motif 
VP2 sequence
133  –  1 4 1 GVNQFAHAL
139  –  147 H A L N V V H D W
143  –  1 5 1 VVHDWGHGL
    Figure 3.         Evolution of the Q9-VP2.139  –  specifi  c CD8 T cell response in K  b    /     D  b    /      mice.   (A) Splenic Q9-VP2.139 tetramer  +   CD8 T cells in unin-
fected, wild-type A2 PyV-infected, or VP2.139 epitope  null   A2.H145A mutant PyV-infected K  b   /   D b   /     mice at day 40 p.i. Plots are gated on CD8  +   cells,  and 
values represent the percentage of cells within the indicated gate. (B) Numbers (left and middle) and frequency (right) of splenic and lung Q9-VP2.139 
tetramer  +   CD8 T cells (  ±  SEM) over time (  n   = 3  –  9 mice at each of the indicated time points). (C) Splenic and lung tetramer  +   cells were analyzed at days 35 
(open) and 178 (shaded) p.i. (plots are representative of four to nine mice at each time point). Plots are gated on CD8  +   Q9-VP2.139  tetramer +   cells.   1652 MHC CLASS IB  –  RESTRICTED ANTIVIRAL CD8 T CELLS   | Swanson et al. 
peak magnitude of the VP2.139-specifi  c CD8 T cell response 
(unpublished data).   The Q9-VP2.139  –  specifi  c CD8 T cells 
constitute 0.5  –  2% of splenic CD8 T cells in B6 responders to 
this epitope, compared with the dominant D  b    –  aa 359  –  368 of 
LT (LT359) CD8 T cell response, which occupied     16% of 
the splenic CD8 T cell compartment in each infected B6 
mouse (  Fig. 6 B  ). As was seen in the K  b    /     D  b    /      mice, only 
a fraction of the Q9-VP2.139  –  specifi  c CD8 T cells in B6 
mice produced IFN-     after peptide stimulation; however, 
K  b    /     D  b    /      mice infected 35 d earlier were injected with 
equal proportions of naive K  b    /     D  b    /      splenocytes pulsed 
with VP2.139 peptide (CFSE  hi   labeled) or left untreated 
(CFSE  lo   labeled). No specifi  c elimination of peptide-coated 
target cells was seen 4 h after injection (unpublished data), 
but after 12 h, infected K  b    /     D  b    /      mice demonstrated sub-
stantial specifi  c clearance of VP2.139-coated targets (  Fig. 4 C  ); 
the longer assay timeframe may enable colocalization of tar-
get cells with the low numbers of VP2.139-specifi  c CD8 T 
cells, which, given their cytokine eff  ector dysfunction, may 
also suff  er reduced cytotoxic eff  ector capability. 
  VP2.139-specifi  c CD8 T cells confer antiviral immunity 
  We used two approaches to directly determine whether 
VP2.139-specifi  c CD8 T cells operated to protect the host from 
viral infection. We fi  rst asked whether K  b    /     D  b    /      mice were 
able to control infection by the VP2.139 epitope  null   mutant 
PyV, A2.H145A. As shown in   Fig. 5 A  , at day 5 p.i. no diff  er-
ences were seen in viral load between the parental and mutant 
viruses in multiple organs (spleen and kidney are shown).   Thus, 
this single mutation at aa 145 in VP2 did not alter the capacity 
of PyV to replicate and disseminate in vivo at a time point pre-
ceding the emergence of a detectable CD8 T cell response (  Fig. 
1 B   and   Fig. 3 B  ). During persistent infection (day 80 p.i.), 
however, K  b    /     D  b    /      mice infected by the A2.H145A virus 
had 100-fold more viral DNA in their kidneys than the parental 
A2-infected animals. This diff  erence was not seen in the spleen 
or salivary glands (unpublished data), possibly pointing toward 
the importance of immune surveillance in an organ prone to 
harboring viruses that persistently infect their hosts (e.g., BK vi-
rus, JC virus, and human CMV). 
  Second, we used an adoptive transfer approach to ask whether 
VP2.139-specifi  c CD8 T cells could protect K  b    /     D  b    /      mice 
against a primary PyV infection. Spleen cells from PyV-infected 
(day 35 p.i.) K  b    /     D  b    /      mice were transferred into naive 
K  b    /     D  b    /      mice that were simultaneously infected either by 
A2 or A2.H145A PyVs. On day 5 p.i., virus levels were signifi  -
cantly lower in recipients of the parental PyV than the VP2.139 
epitope  null   mutant PyV (  Fig. 5 B  ). Collectively, these studies 
indicate that VP2.139-specifi  c CD8 T cells mediate viral clear-
ance in K  b    /     D  b    /      mice. 
  B6 mice generate Q9-VP2.139  –  specifi  c CD8 T cells 
  To determine whether PyV infection elicits Q9-restricted 
VP2.139-specifi  c CD8 T cells in B6 mice, we initially used 
our standard inoculation dose of 10  6   PFU and monitored 
blood and spleen over the course of infection for CD8 T cells 
that bound Q9-VP2.139 tetramers. Under these conditions, 
we were unable to detect VP2.139-specifi  c CD8 T cells (un-
published data). Based on our recent fi  nding that antigen-
nonspecifi  c bystander infl  ammation associated with PyV 
infection impairs the antiviral CD8 T cell response (  33  ), we 
reduced the viral inoculation dose 1,000-fold. As shown in 
  Fig. 6 A  , Q9-VP2.139 tetramers now stained CD8 T cells in 
approximately one third of infected B6 mice at day 11 p.i., the 
    Figure 4.         VP2.139-specifi  c CD8 T cells have reduced effector func-
tion.   (A) Number of Q9-VP2.139 tetramer  +   and  VP2.139  peptide – stimulated 
IFN-    +   CD8 T cells (  ±  SEM) in spleens of K  b   /   D b   /     mice at the indicated 
time points p.i. Values indicate the percentages of IFN-    + /tetramer +   CD8  T 
cells. (B) VP2.139-stimulated spleen cells from K  b   /   D b   /     mice stained for 
intracellular IFN-     and  TNF-    at days 35 and 178 p.i. Plots are gated on 
CD8. (C) Naive K  b   /   D b   /     splenocytes coated with VP2.139 peptide (CFSE  hi ) 
or left uncoated (CFSE  lo  ) were injected into naive or PyV-infected K  b   /   D b   /    
mice (  n   = 3) at day 35 p.i. 12 h later, splenocytes were harvested and ana-
lyzed by fl  ow cytometry. Value indicates the percentage loss of peptide-
coated target cells and is representative of two independent experiments.    JEM VOL. 205, July 7, 2008 
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persistent infection. Naive virus-specifi  c CD8 T cells primed 
de novo during persistent infection are primarily responsible 
for maintaining stable numbers of conventional PyV-specifi  c 
CD8 T cells (  38  ) and are also a source of cells supplying the 
infl  ationary viral epitope  –  specifi  c CD8 T cell populations in 
mouse CMV infection (Snyder, C., K.S. Cho, and A.B. Hill, 
personal communication). Although antigen-driven prolifera-
tion of virus-specifi  c CD8 T cells has been shown to maintain 
CD8 T cell numbers during persistent lymphocytic chorio-
meningitis virus infection (  39  ), PyV-specifi  c MHC class 
Ia  –  restricted T cells undergo gradual attrition and fail to di-
vide in persistently infected wild-type mice (  38, 40  ). Whether 
de novo priming of naive T cells or self-renewal of eff  ector/
memory T cells predominantly accounts for the accumulation 
of VP2.139-specifi  c CD8 T cells in persistently infected 
K  b    /     D  b    /      mice is currently under investigation. The pro-
gressive increase in Q9-VP2.139  –  specifi  c CD8 T cell numbers 
may also suggest that viral capsid proteins are expressed during 
persistent PyV infection. In support of this possibility, VP1 
capsid proteins are expressed in PyV-induced tumors (  41  ) and 
in the kidneys and lungs of persistently infected       2  m      /      mice 
(  22  ). Interestingly, HLA-A2  –  restricted CD8 T cells directed to 
peptides derived from VP1 represent dominant specifi  cities of 
human polyomavirus  –  specifi  c CD8 T cells responses in healthy 
individuals (  42, 43  ). Whether structural proteins are synthe-
sized continuously during low-level   “  smoldering  ”   infection by 
polyomavirus or are transiently resurrected from a dormant 
state is currently unknown. 
  A central fi  nding of this study is that the peripheral T cell 
compartments of both H-2K  b    /     D  b    /      and parental B6 mice 
contain a reservoir of virus-specifi  c Q9-restricted CD8 T cells. 
The character of this response, however, diff  ers depending on 
the level of MHC class Ia suffi   ciency. The Q9-VP2.139  –  spe-
cifi  c CD8 T cell response is strikingly immunodominant in 
K  b    /     D  b    /      mice but constitutes a subdominant, variable re-
sponse in acutely infected B6 mice. A straightforward explana-
tion is that MHC class Ib  –  restricted T cells in K  b    /     D  b    /      mice 
most of the D  b  -restricted LT359-specifi  c CD8 T cells de-
tected by tetramer staining produced IFN-     (  Fig. 6 C  ). Coin-
cident with this functional defi  cit, Q9-VP2.139 CD8 T cells 
express a higher level of surface KLRG1 and a lower level of 
CD127 compared with D  b  -LT359 CD8 T cells (  Fig. 6 D  ). 
Thus, although MHC class Ib  –  restricted antiviral CD8 T cells 
are indeed recruited into the PyV-specifi  c CD8 T cell re-
sponse in acutely infected B6 mice, these T cells appear to be 
more terminally diff   erentiated at this time point than the 
MHC class Ia  –  restricted antiviral CD8 T cells. 
    DISCUSSION   
  In this study, we identifi  ed a novel MHC class Ib peptide li-
gand for virus-specifi  c CD8 T cells and demonstrated that 
these antiviral T cells confer protection against infection. We 
found that the MHC class Ia  –  defi  cient K  b    /     D  b    /      mice effi   -
ciently control infection by PyV and mount an antiviral CD8 
T cell response that is predominantly directed toward a viral 
capsid  –  derived nonamer peptide bound to Q9, a member of 
the Qa-2 family of MHC class Ib molecules. Of the       2  m-
associated MHC class I products encoded in the Qa-2 locus, 
only Q9-restricted T cell responses have been previously 
shown to contribute to host immunity. An early report 
showed that expression of Q9 correlated with resistance to 
mouse cysticercosis (  34  ). More recently, it has been demon-
strated that immunization by Q9-expressing tumor cells elicits 
Q9-restricted CTLs, which are capable of cross-protecting 
against histologically disparate Q9  +   tumors (  35, 36  ). A role for 
Q9-restricted CD8 T cells in antiviral immunity has been 
postulated and is supported by evidence that synthetic pep-
tides from several viral proteins are capable of binding to Q9 
molecules (  37  ). To our knowledge, however, the data pre-
sented in this paper represent the fi  rst identifi  cation of a Qa-
2  –  restricted T cell epitope and the fi  rst description of a MHC 
class Ib  –  restricted virus-specifi  c CD8 T cell response in vivo. 
  An unusual feature of the Q9-restricted CD8 T cell re-
sponse in K  b    /     D  b    /      mice is its steady accumulation during 
    Figure 5.         VP2.139-specifi  c CD8 T cells are protective.   (A)  K b   /   D b   /     mice were infected by parental A2 PyV or the VP2.139 epitope  null   A2.H145A  mutant 
PyV. Levels of PyV DNA (  ±  SEM) in the spleen and kidney were determined by quantitative PCR at the indicated time points p.i. (B) K  b   /   D b   /     mice were in-
fected by A2 or A2.H145A PyVs (10  6   PFU) and simultaneously received 20   ×   10  6   splenocytes from A2 virus  –  infected (day 35 p.i.) K  b   /   D b   /     splenocytes.  Virus 
levels in the indicated organs were assayed as in A at days 5  –  6 p.i. of fi  ve to six mice pooled from two independent experiments. **, P   <   0.0001; *, P   <   0.001.    1654 MHC CLASS IB  –  RESTRICTED ANTIVIRAL CD8 T CELLS   | Swanson et al. 
encoded by an early region transcript and are expressed by both 
productively and nonproductively infected cells. In contrast, 
the VP2.139 epitope is derived from a late-region viral capsid 
protein, whose synthesis is limited to productively infected 
cells. One possibility is that the Q9-VP2.139 CD8 T cell re-
sponse may be at a disadvantage compared with MHC class Ia  –
  restricted LT/MT-specifi  c CD8 T cell responses both in timing 
of expression of the VP2 protein during the PyV lifecycle and 
the number and range of cells presenting the VP2.139 epitope. 
Alternatively, Q9 cell-surface expression, like MHC class Ia 
molecules, is up-regulated by certain infl  ammatory cytokines, 
such as IFN-     (  46  ), and may thus be subject to modulation 
in the context of virus infection. Thus, viral capsid  –  specifi  c 
CD8 T cells may preferentially operate during persistent infec-
tion to contain pockets of active viral infection, a possibility 
supported by evidence that the VP2.139-specifi  c CD8 T cells 
from persistently infected mice control PyV in acutely infected 
recipients (  Fig. 5 B  ). 
  The inability of Q9 to effi   ciently use CD8 coreceptors (  47  ) 
may contribute to the reduced magnitude and eff  ector capabil-
ity of CD8 T cells restricted by this class Ib molecule. Mice 
transgenic for a recombinant MHC class Ia molecule whose     3 
domain was exchanged for that of Q7 (which is identical to Q9) 
(  48  ) show profound ineffi   ciency in the selection of MHC class I 
alloreactive CD8 CTLs. The recently solved Q9 crystal struc-
ture reveals that the AB loop of Q9  ’  s     3 domain points away 
from where it would normally bind CD8 in MHC class Ia mol-
ecules (  24  ). A small pool of VP2.139-specifi  c naive T cells may 
explain the delay in expansion of PyV-specifi  c CD8 T cells in 
K  b    /     D  b    /      mice. Weak CD8 engagement may also raise T 
cell activation thresholds for Q9-restricted T cells, requiring el-
evated epitope densities to achieve full eff  ector potential and 
possibly altering the diff  erentiation of T cells recruited into the 
antiviral response (  49, 50  ). In this connection, it is interesting to 
note that CD8          /      mice mount a delayed, cytokine eff  ector 
function  –  handicapped, H-2D  b    –  restricted PyV-specifi   c T cell 
response (  40  ). 
  The central question is to what extent MHC class Ib  –  re-
stricted T cells contribute to viral immunity. MHC class Ib  –
  restricted CD8 T cells may provide a contingency for the host 
against viral immune evasion. For example, human CMV en-
codes a mimic MHC class Ia leader peptide, UL40, which 
binds to HLA-E and engages inhibitory CD94/NKG2A re-
ceptors on NK cells (  51  ). Yet, HLA-E/UL40  –  specifi  c CD8 T 
cells with cytokine and cytotoxic eff  ector capabilities have 
been isolated from CMV-seropositive individuals (  12  ). From 
a general perspective, MHC class Ib  –  restricted CD8 T cells 
expand epitope diversity of the antiviral immune response and 
protect against immune selection of epitope-escape viral vari-
ants. More specifi  cally, because the dominant antiviral CD8 T 
cell response is directed toward MHC class Ia  –  presented epi-
topes, MHC class Ib  –  restricted T cells may assume impor-
tance as a failsafe antiviral defense strategy. From the surface 
phenotype of the VP2.139-specifi  c CD8 T cells, which sug-
gests recall-competent eff  ector/eff  ector  –  memory cells (  Fig. 3 C  ), 
it is tempting to speculate that MHC class Ib  –  restricted 
would not encounter immunodomination by MHC class Ia  –
  restricted T cells, as described for the H2-M3  –  restricted mem-
ory CD8 T cell response to   L. monocytogenes   (  44  ). Thus, in 
K  b    /     D  b    /      mice, VP2.139-specifi  c CD8 T cells would have 
unfettered access to viral epitope  –  expressing cells, as well as to 
mitogenic and survival cytokines. A related factor may be that 
Q9 surface expression (and presumably Q9 epitope density) is 
higher in K  b    /     D  b    /      mice than in MHC class Ia  –  suffi   cient 
mice (  45  ), possibly because of a lack of competition for       2  m 
and MHC class I chaperone molecules. It is also worth noting 
that to date we have identifi  ed anti-PyV CD8 T cell epitopes 
only from the nonstructural LTs and MTs (  14, 21  ), which are 
    Figure 6.         PyV-infected B6 mice generate a Q9-VP2.139  –  specifi  c 
CD8 T cell response.   (A) Frequency of Q9-VP2.139  +   cells of CD8 T cells in 
the blood, spleen, and lung of PyV-infected (day 11 p.i.) B6 mice (  n   =  32). 
(B) Representative dot plots of splenic Q9-VP2.139 tetramer  +   and  D b -
LT359 tetramer  +   CD8 T cells from B6 mice at day 11 p.i. Plots are gated on 
CD8 T cells. Values indicate percentages of CD8 T cells that are tetramer  + . 
(C) VP2.139 and LT359 peptide  –  stimulated spleen cells from the same 
mice shown in B were analyzed for intracellular IFN-    . Plots are gated on 
CD8 T cells. Values indicate percentages of CD8 T cells that are IFN-    + . 
(D) Expression of the indicated surface molecules by splenic CD8 T cells from 
naive mice (dashed line) and Q9-VP2.139 tetramer  +   (shaded) and D  b -LT359 
tetramer  +   CD8 T cells (continuous line) from infected (day 11 p.i.) B6 mice.     JEM VOL. 205, July 7, 2008 
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prepared on a peptide synthesizer (Symphony/Multiplex; Rainin). The MT 
peptide library includes all of the small T antigen except for its four carboxy-
terminal aa, and the VP2 peptide library covers the entire VP3 sequence. 
  Establishment of PyV-specifi  c CD8 T cell cloned lines.     PyV-spe-
cifi  c CD8 T cells were cloned by limiting dilution from in vitro secondary 
cultures of popliteal lymph node cells from PyV-immune (2  –  3 wk p.i.) 
K  b    /     D  b    /      mice using infected,     -irradiated K  b    /     D  b    /      splenocytes, as 
previously described (  58  ). 
  Cell isolation and fl  ow cytometry.     Single-cell suspensions were made of 
popliteal lymph node cells and RBC-lysed spleens. For lung lymphocyte 
isolation, mice were perfused with PBS containing 100 U/ml heparin, and 
lungs were digested in vitro by collagenase and centrifuged on Percoll step 
gradients, as previously described (  59  ). Antibodies to CD8    , CD43, CD44, 
CD62L, and NKG2A/C/E (clone 20d5) were purchased from BD Biosci-
ences and used according to the manufacturer  ’  s specifi  cations. Anti-CD27, 
anti-CD127, and anti  –  programmed death 1 were purchased from eBiosci-
ence. Anti-KLRG1 was purchased from SouthernBiotech. Q9-VP2.139 tet-
ramers were constructed by the National Institutes of Health Tetramer Core 
Facility at Emory University using cloned full-length Q9 cDNA (  60  ). Tet-
ramer staining was performed, along with antibody surface staining for 35 
min at room temperature in PBS containing 2% FBS and 0.1% sodium azide. 
Samples were acquired on a FACSCalibur (BD Biosciences), and data were 
analyzed using FlowJo software (Tree Star, Inc.). 
  IFN-     ELISPOT assay.     Single-cell ELISPOT assays were performed as 
previously described (  17  ). In brief, 96-well fi  ltration plates (Millipore) were 
coated overnight with anti  –  IFN-     (R4-6A2; BD Biosciences). 2 wk after 
stimulation by infected, irradiated K  b    /     D  b    /      splenocytes, PyV-specifi  c 
K  b    /     D  b    /      CD8 T cell cloned lines were incubated with naive K  b    /     D  b    /      
splenocytes for 36 h at 37  °  C with individual overlapping peptides encom-
passing sequences for MT, LT, VP1, and VP2 PyV proteins. The fi  nal con-
centration of each peptide was     10   μ  M. After the incubation, plates were 
washed and incubated with biotinylated anti  –  IFN-     (XMG1.2; BD Biosci-
ences). Wells were incubated with horseradish peroxidase  –  avidin D (Vector 
Laboratories), washed, and developed with freshly prepared substrate buff  er 
(0.03% [wt/vol] 3-amino-9-ethyl-carbazole and 0.015% [vol/vol] H  2  O  2   in 
0.1 M sodium acetate, pH 5). 
  Intracellular antibody staining.     Cells were stimulated directly ex vivo 
with 1   μ  M VP2.139 peptide for 5 h in the presence of brefeldin A, and were 
then stained for surface CD8 and intracellular cytokines, as previously de-
scribed (  14  ). For assays using CD8 T cell clones, the clones were labeled with 
CFSE to distinguish them from splenic stimulator cells. mAbs to IFN-     and 
TNF-     were purchased from BD Biosciences. For granzyme B staining, 
spleen cells were surface stained directly ex vivo with anti-CD8     and Q9-
VP2.139 tetramers, permeabilized using the Cytofi  x/Cytoperm kit (BD Bio-
sciences), and stained with anti  –  human granzyme B or the isotype control 
antibody (Invitrogen). 
  In vivo CD8 T cell depletion.     CD8     mAb (clone H35; provided by P. 
Allen, Washington University, St. Louis, MO) (  61  ) was prepared in fl  asks 
(INTEGRA Celline CL1000; Integra Biosciences) using defi  ned IgG-free 
medium (Invitrogen), according to the manufacturer  ’  s instructions. 1 mg 
anti-CD8     or ChromPure rat IgG (Jackson ImmunoResearch Laboratories) 
was administered i.p. on days     3,     1, and +1 from the day of PyV infec-
tion, with antibodies given every 5 d up to day 30 p.i. No CD8    -expressing 
CD3  +   T cells were detected in spleens of CD8     mAb  –  treated mice at day 
35 p.i. (unpublished data). 
  In vivo cytotoxicity assay.     RBC-lysed, single-cell spleen suspensions 
from naive K  b    /     D  b    /      mice were pulsed at 10  7   cells/ml with 10   μ  M 
VP2.139 peptide or without peptide in DMEM containing 10% FBS for 
30 min at 37  °  C. Each cell population was stained at 10  7   cells/ml in HBSS 
(Invitrogen) with 2 mM CellTrace Far Red DDAO-SE (Invitrogen) at 
T cells may be play a substantial role in limiting persistent 
viral infection. 
  Because MHC class Ib molecules have few polymor-
phisms, identifi   cation of MHC class Ib  –  restricted epitopes 
would off  er much more comprehensive coverage across a 
population for peptide-based CD8 T cell  –  mediated immuno-
therapy than can be achieved by immunization using MHC 
class Ia  –  restricted peptides. Although Q9 is a mouse-only 
MHC class Ib molecule, HLA-G has been proposed to con-
stitute its functional human homologue (  52  ). It is also notable 
that PyV is unique among avian and mammalian polyomavi-
ruses in possessing a VP2.139 sequence available for binding 
to Q9 (  53  ). This apparent example of host  –  pathogen coevo-
lution lends additional support toward uncovering MHC class 
Ib  –  restricted antiviral CD8 T cell responses in humans, with 
the prospect of developing seemingly   “  non  –  MHC-restricted  ”   
epitope-based vaccinations for viral infections. 
  MATERIALS AND METHODS 
  Mice.     C57BL/6NCr (B6) female mice were purchased from the Frederick 
Cancer Research and Development Center of the National Cancer Institute. 
H2-K  b    /     D  b    /      (K  b    /     D  b    /     ) mice (  45  ) were obtained from Taconic. H2-
M3      /      (  54  ), CD1d      /      (  55  ), Qa-1b      /      (  56  ), and B6.K1 (  57  ) mice have been 
previously described. Spleens from Qa-1b      /      mice were provided by H. Cantor 
(Dana-Farber Cancer Institute, Boston, MA). K  b    /     D  b    /      mice were bred and 
housed by the Department of Animal Resources at Emory University in accor-
dance with the guidelines of the university  ’  s Institutional Animal Care and Use 
Committee. All mice were between 6 and 8 wk of age at the time of infection. 
  Cell lines.     The derivation and maintenance of the B78H1 transfectants ex-
pressing TAP2 (designated H1TAP.11), TAP2 and Q8 (designated 
H1Q8TAP.11), or TAP2 and Q9 (designated H1Q9TAP.11) have been pre-
viously described (  25  ). 
  Viruses and cell transfers.    K  b    /     D  b    /      and B6 mice were infected s.c. by 10  6   
and 10  3   PFU of PyV (A2 strain), respectively, in hind footpads. The A2.H145A 
mutant virus was created using PCR-based site-directed mutagenesis of A2 
genomic DNA (forward primer, 5    -GCTCTAAATGTAGTA  GC  TGATT-
GGGGCCATGGC-3    ; reverse primer, 5    -GCCATGGCCCCAATCA  GC  -
TACTACATTTAGAGC-3    ; mutation nucleotides are underlined) to change 
the codon for aa 145 in the VP2 protein from histidine to alanine. A VP2.139-
147 (145A) analogue peptide did not stimulate spleen cells from PyV-infected 
K  b    /     D  b    /      mice, and A2.H145A-infected K  b    /     D  b    /      mice did not gener-
ate VP2.139-specifi  c CD8 T cells (unpublished data). 20   ×   10  6   spleen cells 
from K  b    /     D  b    /      mice at day 35 p.i. by wild-type PyV were transferred i.v. 
to naive K  b    /     D  b    /      mice, which were inoculated immediately after transfer 
with 10  6   PFU of parental A2 or mutant A2.H145A PyV. 
  Quantitation of PyV genomes.     DNA isolation and Taqman-based real-
time PCR were performed as previously described (  14  ). PyV DNA quan-
tity is expressed in genome copies per milligram of tissue and is calculated 
based on a standard curve of known PyV genome copy numbers versus 
threshold cycle of detection. The detection limit with this assay is 10 copies 
of genomic viral DNA. 
  Synthetic peptides.     VP2.133-141, VP2.139-147, and VP2.143-151 peptides 
(  Table II  ) and LT359-368Abu peptide (  33  ) were synthesized by the solid-
phase method using F-moc chemistries. Peptide stocks were solubilized in wa-
ter or DMSO and stored at   –  20  °  C. Peptides were diluted in assay medium 
immediately before use. The MT and LT peptide libraries, consisting of 17mer 
peptides overlapping by 12 aa, were prepared as PepSets by Chiron and were 
provided by J. Altman (Emory Vaccine Center, Atlanta, GA); the VP1 and 
VP2 peptide libraries, consisting of 15mer peptides overlapping by 10 aa, were 1656 MHC CLASS IB  –  RESTRICTED ANTIVIRAL CD8 T CELLS   | Swanson et al. 
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